International collaborative actions and transparency to understand, diagnose, and develop therapies for rare diseases
Abstract Rare diseases, which affect over 350 million people worldwide and frequently go undiagnosed or misdiagnosed for years, suffer from sparse and dispersed medical knowledge leading to even rarer approved and effective therapeutic options for patients. A vast, unmet need for research and invest...
Saved in:
| Main Authors: | Kym M Boycott, Lilian PL Lau, Christine M Cutillo, Christopher P Austin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2019-04-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201910486 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Transparency in Open Science: An Actionable Principle?
by: Cruz Romero Roberto
Published: (2025-05-01) -
Transparency and Corruption Prevention in Financing Climate Action
by: Victoria Bozhenko, et al.
Published: (2023-06-01) -
Understanding Transparency Failures: When Sunshine Causes Sunburns
by: Jean-Patrick Villeneuve, et al.
Published: (2025-07-01) -
Understanding the Value of a Digital Equity Researcher-Practitioner Collaboration Using Participatory Action Research
by: Colin Rhinesmith, et al.
Published: (2025-05-01) -
Addressing gaps in our understanding of the drowning patient: a protocol for the retrospective development of an Utstein style database and multicentre collaboration
by: Amy E Peden, et al.
Published: (2023-02-01)